Acute pancreatitis caused by tigecycline and furosemide combination treatment and hypofibrinogenemia caused by tigecycline: A case report

作者：Zhi Li, Ping Zheng · 发表于：International Journal of Clinical Pharmacology and Therapeutics · 年份：2023 · DOI：10.5414/cp204337 · 被引用次数：8 · 研究领域：Pancreatitis Pathology and Treatment、Heparin-Induced Thrombocytopenia and Thrombosis、Pancreatic and Hepatic Oncology Research

OBJECTIVE: We describe a case of acute pancreatitis (AP) and hypofibrinogenemia associated with drug treatment with the aim to increase awareness of uncommon yet possibly life-threatening adverse reactions of tigecycline and furosemide. CASE SUMMARY: day of hospitalization, the patient presented with acute upper gastrointestinal bleeding and decreased levels of fibrinogen and platelets. After withdrawal of tigecycline, the coagulation and pancreatitis parameters improved significantly. However, the pancreatitis parameters increased again after stopping somatostatin. Therefore, somatostatin was given again for 1 day, and furosemide was discontinued. After that, the pancreatitis parameters returned to baseline levels after a slight recovery. CONCLUSION: Clinicians should pay attention to clinical signs, symptoms, and pancreatic enzymes during tigecycline or furosemide treatment, especially when used in combination. In addition, regular monitoring of fibrinogen and platelet count during tigecycline treatment is suggested.